

## Letter to the Editors

Dear Sirs,

16th February 2000

### *On the Use of Botulinum Toxin*

In the last issue of the journal, in an article on botulinum<sup>1</sup>, we indicated that, in our experience, the maximum dosage of botulinum (Dysport) which can be given safely at one session is 30 units per kilogram or 1500 units in total. More recent studies by ourselves and others support the use of 30 units per kilogram as a maximum dose. The total dose, however, should not exceed 1000 units in total. We would like to bring this to the attention of your readers.

Yours sincerely

Richard Morton  
Paediatric Consultant  
Ronnie Mackeith Child Development Centre and Derbyshire Children's Hospital

### *Reference*

1. Morton R, Murray-Leslie C. The use of botulinum toxin for children with cerebral palsy. *Paed Peri Drug Ther* 1999; 3: 4-8.

## ***European Society for Developmental Pharmacology Seventh Congress, Jerusalem, November 25th-28th, 2000***

The Seventh Congress of the European Society will be held in Jerusalem and will involve the following:

### ***State of the Art Lectures***

- Pain in Children
- Glycans and Inflammation
- Pharmacoeconomics in Children
- Drugs in the Developing World

### ***Symposia***

- Prostaglandins and COX inhibitors
- Genetics and Pharmacotherapy
- Methodological Issues in Drug Evaluation in Children
- Anti-infective Therapy and Vaccines

### ***Workshop***

- Research and Licensing of Drugs in Children

### ***Oral Free-communication Sessions***

### ***Poster Free-communication Sessions***

### ***Publication of Abstracts***

- Abstracts Accepted for Presentation will be Published here in *Paediatric and Perinatal Drug Therapy*

### ***Further Information from:***

Rafael Gorodischer, MD, Department of Pediatrics. Soroka Medical Center  
PO Box 151, Beer-Sheva, Israel 84101  
Tel: +972-7-6400546  
Tel: +972-7-6400016  
email: rafaalg@bgumail.ac.il

## Instructions to Authors

1. All manuscripts should be in the English language. Submission of manuscripts as both hard-copy and word-processor files facilitates rapid publication. Most common word-processor formats are acceptable, although Microsoft Word is preferred. Typewritten material should be prepared double-spaced and on one side of the paper only. Two copies should be supplied. Any handwritten corrections or photocopies of the original manuscript should be clearly legible. Each paper should contain the following: (a) a short descriptive title, (b) the name(s) and initials of the author(s), (c) the Centre at which the work was carried out or the location of the author(s), (d) a summary or abstract of the main facts and results, (e) an Introduction, (f) separate main sections, (g) a final Discussion or Conclusions section, (h) any acknowledgements and (i) full references to relevant material in the text. Authors are also requested to supply approximately six 'key words', in English, preferably from the Index Medicus Medical Subject Heading (MeSH) list.
2. All drugs and other compounds should be referred to by their internationally accepted generic names and not by individual company trade marks, unless it is essential for clarity, as in the case of combination products, or to avoid confusion, e.g. between different formulations.  
Specialised abbreviations and symbols should not be used unless first explained in the text. Dosages and measurements should be given in the units in which they were made, but non-metric units should be accompanied by metric (SI) equivalents.
3. Acknowledgement must be given by authors of grants, fellowships, or any commercial assistance received or of any affiliation which is relevant to the work reported.
4. All references should be individually numbered in Arabic numerals and cited where they appear in the text. At the end of the paper, references should be listed in strict numerical order. The names of all authors for each reference must be given (unless there are six or more, in which case the first three should be listed, followed by 'et al.'). They should be followed by: (a) the full title of the paper, (b) the year of publication, (c) the abbreviated title of the journal (ANSI/BSI system), and (d) the volume and page number(s). Reference to books must give the publisher, place and year of publication, name(s) of the editor(s) where authorship is multiple, and first page number of chapter referred to.
5. All tables and illustrations should be provided with short descriptive legends, numbered consecutively, and their relevant position in the text clearly indicated. Tables should have concise headings to all columns and be identified by Arabic numerals, e.g. Table 2. They should be supplied within the files on disk in cellular form rather than in simple tabbed form. Line diagrams should be supplied both as files on disk in either .TIF or .EPS format and in the format of the program used to produce them. If this is not possible, they should be supplied in a suitable finished form for reproduction and in proportion to the single-column width (80 mm) or double-column width (165 mm). Photographic illustrations will usually be accepted. Illustrations should also be identified by Arabic numerals, e.g. Figure 2.
6. Papers are published on the understanding that their copyright becomes the property of the Publishers once they are accepted for publication. Authors must state clearly if the paper is being actively considered for publication or has been published elsewhere in the world. If subject to copyright (and this includes illustrations), copyright clearance is the sole responsibility of the author and must be supplied in writing to the Publishers. Papers first published in *Paediatric and Perinatal Drug Therapy* must not be translated, abridged or reprinted in any form elsewhere in the world without the written consent of the Publishers.
7. Proofs in page form will be sent to the main author for checking provided that this will not result in delayed publication of any issue of the journal. If, because of postal delays, etc. time is limited, the Publishers reserve the right to have proofs checked against original manuscripts by their editorial staff and/or the editors. No major alterations to text will be accepted at proof stage.